Compare FEIM & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FEIM | FDMT |
|---|---|---|
| Founded | 1961 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 439.6M | 479.9M |
| IPO Year | 1994 | 2019 |
| Metric | FEIM | FDMT |
|---|---|---|
| Price | $57.52 | $9.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $51.50 | $31.71 |
| AVG Volume (30 Days) | 134.4K | ★ 598.4K |
| Earning Date | 03-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 316.95 | 18.79 |
| EPS | ★ 0.41 | N/A |
| Revenue | $69,811,000.00 | ★ $85,209,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $21.73 | $70.28 |
| P/E Ratio | $146.74 | ★ N/A |
| Revenue Growth | 26.30 | ★ 230194.60 |
| 52 Week Low | $17.56 | $3.37 |
| 52 Week High | $64.99 | $12.34 |
| Indicator | FEIM | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 52.59 | 44.50 |
| Support Level | $42.53 | $8.45 |
| Resistance Level | $59.75 | $9.78 |
| Average True Range (ATR) | 4.20 | 0.61 |
| MACD | 0.35 | -0.01 |
| Stochastic Oscillator | 60.10 | 23.74 |
Frequency Electronics Inc is engaged in the design, development, and manufacture of high-precision timing, and frequency control products for space, air, sea, and terrestrial applications. The company has FEI-NY and FEI-Zyfer reportable segments. It derives the majority of its revenues from the FEI-NY segment. FEI-NY segment operations consist principally of precision time and frequency control products used in three principal markets namely communication satellites (both commercial and U.S. Government-funded); terrestrial cellular telephone or other ground-based telecommunication stations; and other components and systems for the U.S. military.
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).